The arrival of Vertex's (VRTX) Incivek in 2010 kicked off a significant jump in the costs of treating hepatitis C. Those costs are likely to surge higher once Gilead's (GILD) and Johnson & Johnson's (JNJ) new drugs launch.
TheStreet highlights 3 stocks pushing the health care sector lower today.
TheStreet contributor David Sobek offers seven forecasts for biotech stocks in 2014.
Despite discounts on drugs, certain drugmakers look poised to benefit from increased enrollment in Obamacare.
Johnson & Johnson beats Gilead Sciences to deliver the first next-generation hepatitis C drug approved in the U.S., but a battle with Vertex Pharmaceuticals' and Merck's first-generation drugs will be short lived with Gilead and AbbVie developing all-oral cocktails.
Vertex Pharmaceuticals was a winner within the health care sector, rising $1.68 (2.5%) to $67.96 on light volume
Stocks with insider trader activity include BSX, VNDA, RLGY, SNDK and VRTX
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
This deal is in line with Vertex Pharma's efforts to move away from its HCV franchise and focus on the cystic fibrosis franchise.
Vertex sells royalty rights to hepatitis C drug Incivo to partner Johnson & Johnson for $152 million.
Inovio, ImmunoGen, Roche, and Johnson & Johnson are all making headlines this morning. Here’s why.
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as an unusual social activity candidate
Stocks with insider trader activity include GPI, VRTX, ICON, FCS and IMPV
If this Kalydeco study is positive, Vertex will be able to market the drug to another 1,100 cystic fibrosis patients.